Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carolina Ibáñez has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and Safety of Adjusting Antimicrobial Therapy in Episodes of Fever and Neutropenia Catalogued as Fever of Unknown Origin in Children with Cancer: A Randomized Clinical Trial

    by Carolina Ibáñez, Romina Valenzuela, Marlon Barraza, Ana M. Álvarez, Ernesto Paya, Verónica Contardo, Valentina Gutiérrez, Karen Ducasse, Juan P. Torres, Paulina Coria, et al.

    Background/Objectives: The objective of this study is to evaluate the efficacy and safety of maintaining antimicrobial (AM) therapy or adjusting AM therapy during episodes of febrile neutropenia (FN) catalogued as a fever of unknown origin (FUO) in children with cancer. Methods: This is a prospective, multicenter, noninferiority, randomized study, approved by ethics committee, in children with episodes of FN in eight hospitals in Chile. Microbiological and molecular samples were drawn at admission. Patients with FUO (negative bacterial and viral study with no clinical focus suggesting infection) and favorable evolution during the first 48–72 h of AM therapy were randomized 1:1 to maintain or adjust treatment, reducing the number and spectrum of AMs. The primary endpoint was the percentage of episodes with an uneventful resolution; the secondary endpoints were the re-adjustment of AM therapy, days of fever/hospitalization/AM therapy, days of vancomycin and meropenem per 1000 days of neutropenia, number of AMs after randomization, pediatric intensive care unit (PICU) admission, sepsis, and death. Results: A total of 266 of 939 FN episodes recruited between March 2021 and January 2024 were catalogued as FUO, of which 231 had a favorable evolution at 48–72 h and were randomized, 111 to maintain and 120 to adjust AM therapy. Both groups presented the same percentage of uneventful resolution, with 106 (96%) in the group that maintain AM therapy and 114 (95%) in the adjusted group (p = 1.00); relative risk 1.01, (95%CI 0.95–1.06); absolute risk difference 0.01, (95%CI −0.05–0.06). Conclusions: The main finding of this study demonstrates that adjusting antimicrobial therapy appears safe in carefully selected FUO cases with a favorable early evolution, during episodes of FN catalogued as FUO in children with cancer. These findings open an opportunity to new AM stewardship strategies in this population, with a possible future impact on AM resistance.

  • Clinical Outcome, Microbiologic Etiology and Pulmonary Tomographic Findings in Children With Cancer and Episodes of Persistent High-risk Febrile Neutropenia

    by Carolina Ibáñez, Daniza Jaldin, Romina Msc Valenzuela, Verónica Msc de la Maza, Lizbet Pérez, Isabel Fuentealba, Juan P. Torres, María E. Santolaya

    Background: Febrile neutropenia (FN) is one of the most frequent complications of antineoplastic treatment in patients with cancer. Invasive bacterial infections and invasive fungal infections are a major cause of morbidity and mortality in this population, along with respiratory viral infections, which are increasingly recognized in children with FN episodes. Objectives: This study aimed to compare the clinical outcome of children with persistent high-risk FN (HRFN) that have an abnormal chest computed tomography (CT) versus those with normal chest CT or in which chest CT was not indicated, and to evaluate the microbiologic etiology and pulmonary tomographic findings in this population. Methods: Patients with persistent HRFN were prospectively enrolled between 2016 and 2021 and classified into 2 groups: children with persistent HRFN that had an abnormal chest CT and children that had a normal chest CT or in which chest CT was not clinically indicated. We compared the clinical outcome of the patients of the 2 groups. Children with abnormal chest CT underwent a microbiologic and molecular study to evaluate the etiology of the pulmonary compromise. After discharge, all children with persistent HRFN that had an abnormal chest CT were evaluated by 2 groups of independent, blind investigators: 1 pediatric infectious disease specialist that classified the etiology of the pulmonary infiltrate as bacterial, fungal, viral or unknown etiology and 2 pediatric radiologists that classified each chest CT, as defined by the Fleischner Society. Results: We enrolled 176 children with persistent HRFN, of which 36 had abnormal chest CT. In 27/36 episodes (75%), the etiology was determined (12 bacterial, 8 viral and 7 fungal). Subjects with an abnormal chest CT had more days of fever, longer length of hospital stay, higher PICU admission, more use of mechanical ventilation, more oxygen requirement, longer periods of antibacterial and antifungal therapy. Chest CT showed no statistically significant differences when findings were compared by etiology of the episodes. Conclusions: Our results strongly support that abnormal findings on chest CT in children with persistent HRFN should be interpreted as a predictor of poor clinical outcome, as not as a marker of etiology.


  • Clinical Outcome in Children With Cancer With Two or More Microorganisms Isolated From Blood Cultures During Episodes of Fever and Neutropenia

    by Carolina Ibáñez, Juan Pablo Torres, Verónica De La Maza, Salome Rivera, Romina Valenzuela, Maria Elvira Simian, Ernesto Payá, Ana María Álvarez, Verónica Contardo, Daniela Martínez, et al.

    Background: Bacterial bloodstream infections are a major cause of morbidity and mortality in children with cancer and episodes of fever and neutropenia (FN). The aim of this study was to evaluate the clinical outcome in children with cancer with 2 or more microorganisms isolated from blood cultures during their episodes of FN. Methods: Between 2016 and 2021, children presenting with high-risk FN, admitted to any of the 6 participating hospitals in Santiago, Chile, were included in this study if they have positive blood cultures. We compared the clinical outcome of children with 2 or more microorganisms versus those with single agent isolation. Results: A total of 1074 episodes of high-risk FN were enrolled in the study period, of which 27% (298) had positive blood cultures and 3% (32) had 2 or more microorganisms isolated from blood cultures. The most frequent identified agents were Viridans group streptococci and Escherichia coli in 20%, followed by Coagulase negative staphylococci in 14%. Children with 2 or more microorganisms presented more days of fever (7 vs. 4 days, P = 0.02), needed longer courses of antimicrobial therapy (16 vs. 14 days, P = 0.04) and had higher mortality at day 30 (13% vs. 1%, P = 0.003). Conclusions: Children with cancer and FN with 2 or more microorganisms isolated from blood cultures had a worse clinical outcome than children with single agent isolation.


  • Open Access

    Oncological resection, myasthenia gravis and staging as prognostic factors in thymic tumours: a Chilean case series

    by Patricio Salas, Maria Eliana Solovera, Felipe Bannura, Matias Muñoz-Medel, Miguel Cordova-Delgado, Cesar Sánchez, Carolina Ibáñez, Marcelo Garrido, Érica Koch, Francisco Acevedo, et al.

    Oncological resection, myasthenia gravis and staging as prognostic factors in thymic tumours: a Chilean case series Patricio Salas1, Maria Eliana S

  • Open Access

    Vacunas SARS CoV-2, estudios en fase III

    by Carolina Ibáñez Guelfenbein, Juan Pablo Torres Torretti, María Elena Santolaya de Pablo

    La enfermedad por coronavirus 2019, causada por el virus SARS-CoV2, fue declarada pandemia en marzo de 2020 por la OMS. La proteína S, de la superficie viral ha sido identificada como antígeno óptimo para el desarrollo de vacunas. En pandemia, el proceso tradicional de desarrollo de vacunas ha debido acelerarse para avanzar en una respuesta adecuada al problema, acortando los tiempos. La seguridad, inmunogenicidad, protección frente a la infección, fenómeno de “aumento dependiente de anticuerpos”, duración de la protección se estudian en paralelo, a diferencia de la manera tradicional en que se llevaba a cabo en etapas sucesivas. Actualmente en Fase III hay 4 tipos vacunas: inactivadas; en base a proteínas purificadas o recombinantes, en base a ácidos nucleicos ADN/ARN y en base a vectores virales. El objetivo de esta revisión es conocer los estudios que preceden a las vacunas que actualmente están en estudios de Fase III y describir las características principales de estos estudios. Actualmente el mundo se encuentra en una situación inédita en el último siglo. Dentro las opciones para enfrentar este hecho, una vacuna o idealmente varias, seguras, eficaces e inmunogénicas, parecen ser una de las mejores alternativas para retomar en un plazo razonable la normalidad perdida.


  • Open Access

    Phase II Trial of SBRT and Hormone Therapy for Oligometastases in Prostate Cancer

    by A.J. Conde-Moreno, F. Lopez, A. Hervas, T. Piquer Camanes, A. Mendez, M.D.M. Puertas, J.J. Valero, A. Gomez Iturriaga, M. Rico, M.L. Vázquez de la Torre, et al.